Future paradigms for precision oncology.

Autor:	Klement GL; Department of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA.; Department of Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA., Arkun K; Department of Pathology, Tufts Medical Center, Boston, MA, USA., Valik D; Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic.; Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic., Roffidal T; Department of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA., Hashemi A; CSTS Health Care®, Toronto, Canada., Klement C; CSTS Health Care®, Toronto, Canada., Carmassi P; CSTS Health Care®, Toronto, Canada., Rietman E; CSTS Health Care®, Toronto, Canada.; Computer Science Department, University of Massachusetts, Amherst, MA, USA., Slaby O; Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic.; Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Mazanek P; Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic.; Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic., Mudry P; Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic.; Regional Center for Applied Molecular Biology, RECAMO, Brno, Czech Republic., Kovacs G; 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary., Kiss C; Department of Pediatric Hematology-Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Norga K; Antwerp University Hospital, Edegem, Belgium., Konstantinov D; Specialized Children's Oncohematology Hospital, Sofia, Bulgaria., André N; Department of Pediatric Hematology and Oncology, AP-HM, Marseille, France.; UMR S_911 CRO2 Aix Marseille Université, Marseille, France., Slavc I; Department of Pediatrics, Medical University of Vienna, Vienna, Austria., van Den Berg H; Department of Pediatric Oncology, Emma Children Hospital Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands., Kolenova A; Department of Pediatric Oncology, Comenius University, Bratislava, Slovakia., Kren L; Department of Pathology, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic., Tuma J; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Pediatric Surgery, University Hospital Brno, Brno, Czech Republic., Skotakova J; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic., Sterba J; Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; ICRC St. Anna University Hospital Brno, Brno, Czech Republic.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2016 Jul 19; Vol. 7 (29), pp. 46813-46831.
DOI:	10.18632/oncotarget.9488
Abstrakt:	Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types.This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required.While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used. Competing Interests: There is no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu